Research warns of heart risks from newer antipsychotics

01/14/2009 | Reuters

Researchers who examined records from the Tennessee Medicaid program found that those who take newer "atypical" medicines for schizophrenia and other psychiatric disorders had double the risk of heart attack compared with nonusers. Among the drugs cited are AstraZeneca's Seroquel, Eli Lilly and Co.'s Zyprexa and Johnson & Johnson's Risperdal.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA